Abstract:There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.

The Therapeutic Effect of SCFA-Mediated Regulation of the Intestinal Environment on Obesity

Dietary Fiber and Its Potential Role in Obesity: A Focus on Modulating the Gut Microbiota

Gut microbial metabolite short-chain fatty acids and obesity

Gut microbiota and obesity: implications for fecal microbiota transplantation therapy

An overview of traditional Chinese medicine affecting gut microbiota in obesity

From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?

The Gut Microbial Regulation of Epigenetic Modification from a Metabolic Perspective

Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders

The Role of Gut Microbiota Modulation Strategies in Obesity: The Applications and Mechanisms

The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities

Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases

The critical role of gut microbiota in obesity

Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease

Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake

Gut Microbiota and Obesity: Focus on Hormone Regulation and Appetite Control

[The Intestinal Microbiota and Obesity of the Host].

Butyrate and obesity: Current research status and future prospect

Gut microbiota and therapy for obesity and type 2 diabetes

Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota

Dietary fiber‐derived short‐chain fatty acids: A potential therapeutic target to alleviate obesity‐related nonalcoholic fatty liver disease